ESC 2022 – factor XI inhibitors crash
Development continues, but multi-billion dollar forecasts for this new anticoagulant class must now be in doubt.
Drug makers leave the pain behind
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
